Abstract
MET exon 14 (METex14) skipping activates oncogenic MET signaling in 3-4% of patients with non-small cell lung cancer (NSCLC). The low frequency of this alteration has influenced the investigation of MET inhibitors, often leading to an open-label, single-arm trial design, in order to maximize the number of patients receiving these compounds. One example is the global Phase II VISION single-arm study of the oral, highly selective MET inhibitor tepotinib in patients with METex14 skipping NSCLC, in which tepotinib demonstrated robust and durable activity with an objective response rate of 49.1% (data cut off: Feb 1, 2021).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
